Amarin Corporation plc (ADR) (NASDAQ:AMRN) announced the presentation of findings from two studies, a retrospective study in which patients were switched from an EPA plus DHA combination product to EPA-only Vascepa® (icosapent ethyl) as well as a sub-analysis of the ANCHOR clinical trial, at two key cardiovascular meetings: the American Society for Preventive Cardiology Annual Cardiovascular Disease Prevention Conference (July 31-August 2, Boca Raton, FL) and the Kern Lipid Conference (August 3-5, Vail, CO), respectively.
The EPA+DHA to EPA-only switch study, titled Retrospective Case Series of Lipid Effects in Patients Switched from EPA+DHA (Omega-3-Acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl), investigated the effect of EPA-only omega-3 therapy compared to EPA+DHA therapy on multiple patient lipid parameters. Building on the results of prior retrospective case studies, results of this case series showed a reduction in both triglyceride and low-density lipoprotein cholesterol (LDL-C) levels with EPA-only therapy in most of these high-risk statin-treated patients. The poster will be on display at the ASPC Annual Cardiovascular Disease Prevention Conference from July 31 – August 1, with a poster Q&A session taking place on Saturday, August 1, from 12:45PM – 1:45PM with lead author Dr. James R. Crandell, St. John Medical Center, Lakewood, Ohio.
The ANCHOR sub-analysis, titled Effects of Icosapent Ethyl, a Highly Purified Eicosapentaenoic Acid Ethyl Ester, on the Fatty Acid Profile in Plasma and Red Blood Cells in Statin-Treated Patients with Persistent High Triglycerides (Results from the ANCHOR Study), is an encore presentation (originally presented at the American Heart Association Scientific Sessions, 2012). The study examined the effect of EPA on high-risk statin-treated patients with persistently high triglyceride levels, showing that icosapent ethyl increased EPA in plasma and red blood cells in a linear, dose-dependent fashion consistent with its triglyceride-lowering effect. Data will be presented as a poster at the Kern Lipid Conference on Monday evening, August 3 by Dr. Rebecca A. Juliano, Executive Director of Clinical Development at Amarin.
The two presentations add to the growing literature on the effects of EPA treatment on high-risk patients with dyslipidemia. Additional studies are needed to determine if the effects of EPA shown in these studies would have clinically meaningful benefit. (Original Source)
Shares of Amarin Corporation Plc closed yesterday at $2.20. AMRN has a 1-year high of $3.33 and a 1-year low of $0.78. The stock’s 50-day moving average is $2.38 and its 200-day moving average is $2.00.
Amarin Corp PLC is a biopharmaceutical company with expertise in lipid science. The Company is engaged in commercialization and development of therapeutics to improve cardiovascular health.